{
  "source": "PA-Notification-Benlysta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1227-10\nProgram Prior Authorization/Notification\nMedication Benlysta® (belimumab)*\n*This program applies to the subcutaneous formulation of belimumab\nP&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 2/2021, 7/2021, 4/2022, 7/2022,\n7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nBenlysta® is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment\nof patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are\nreceiving standard therapy and in patients aged 5 years and older with active lupus nephritis\nwho are receiving standard therapy.\nLimitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe\nactive central nervous system lupus. Use of Benlysta is not recommended in this situation.\n2. Coverage Criteriaa:\nA. Systemic Lupus Erythematosus\n1. Initial Authorization\na. Benlysta will be approved based on all of the following criteria:\n(1) Diagnosis of systemic lupus erythematosus\n-AND-\n(2) Patient is currently receiving standard immunosuppressive therapy [e.g.,\nhydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate]\n-AND-\n(3) Patient does not have severe active central nervous system lupus\n-AND-\n(4) Patient is not receiving Benlysta in combination with any of the following:\n(a) Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira\n(adalimumab), Cimzia (certolizumab), Kineret (anakinra)]\n(b) Lupkynis (voclosporin)\n(c) Saphnelo (anifrolumab-fnia)\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\n2. Reauthorization\na. Benlysta will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Benlysta therapy\n-AND-\n(2) Patient is not receiving Benlysta in combination with any of the following:\n(a) Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira\n(adalimumab), Cimzia (certolizumab), Kineret (anakinra)]\n(",
    ") Patient is not receiving Benlysta in combination with any of the following:\n(a) Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira\n(adalimumab), Cimzia (certolizumab), Kineret (anakinra)]\n(b) Lupkynis (voclosporin)\n(c) Saphnelo (anifrolumab-fnia)\nAuthorization will be issued for 12 months.\nB. Active Lupus Nephritis\n1. Initial Authorization\na. Benlysta will be approved based on all of the following criteria:\n(1) Diagnosis of active lupus nephritis\n-AND-\n(2) Patient is currently receiving standard immunosuppressive therapy for systemic\nlupus erythematosus [e.g., hydroxychloroquine, chloroquine, prednisone,\nazathioprine, methotrexate]\n-AND-\n(3) Patient does not have severe active central nervous system lupus\n-AND-\n(4) Patient is not receiving Benlysta in combination with any of the following:\n(a) Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira\n(adalimumab), Cimzia (certolizumab), Kineret (anakinra)]\n(b) Lupkynis (voclosporin)\n(c) Saphnelo (anifrolumab-fnia)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Benlysta will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n2\n(1) Documentation of positive clinical response to Benlysta therapy\n-AND-\n(2) Patient is not receiving Benlysta in combination with any of the following:\n(a) Targeted Immunomodulator [e.g., Enbrel (etanercept), Humira\n(adalimumab), Cimzia (certolizumab), Kineret (anakinra)]\n(b) Lupkynis (voclosporin)\n(c) Saphnelo (anifrolumab-fnia)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval an",
    "overage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• The intravenous infusion is typically covered under the medical benefit. Please refer to the\nUnitedHealthcare Drug Policy for Benlysta.\n4. References:\n1. Benlysta [package insert]. Durham, NC: GlaxoSmithKline; May 2024.\nProgram Prior Authorization/Notification - Benlysta (belimumab)\nChange Control\n9/2017 New program.\n9/2018 Annual review with no changes to coverage criteria. Updated\nreference.\n9/2019 Annual review with no changes to coverage criteria. Updated\nbackground to align with updated FDA label. Updated reference.\nAdded general NCCN recommended review criteria.\n9/2020 Annual review. Updated reauthorization duration. Removed NCCN\nrecommended review criteria. Updated reference.\n2/2021 Off cycle review. Background and clinical criteria updated to align\nwith updated FDA label for new indication for adult patients with active\nlupus nephritis who are receiving standard therapy. References\nupdated.\n7/2021 Added not to be used in combination with Lupkynis to criteria.\n4/2022 Added not to be used in combination with Saphnelo (anifrolumab-fnia)\nto criteria. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n3\n7/2022 Annual review with no changes to coverage criteria. Added state\nmandate disclaimer.\n7/2023 Annual review. Updated background. Updated coverage criteria for\nSLE removing documentation of the presence of antibodies. Updated\nnot used in combination from biologic DMARD to targeted\nimmunomodulator without change in clinical intent. Updated reference.\n7/2024 Annual review with no changes to coverage criteria. Updated\nreference.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}